| Dr Jennifer Joy Hamm, PHARMD | |
|
389 Johnnie Dodds Blvd, Mount Pleasant, SC 29464-2932 | |
| (843) 972-4068 | |
| Not Available |
| Full Name | Dr Jennifer Joy Hamm |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 389 Johnnie Dodds Blvd, Mount Pleasant, South Carolina |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417426594 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 37694 (South Carolina) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jennifer Joy Hamm, PHARMD 389 Johnnie Dodds Blvd, Mount Pleasant, SC 29464-2932 Ph: (843) 972-4068 | Dr Jennifer Joy Hamm, PHARMD 389 Johnnie Dodds Blvd, Mount Pleasant, SC 29464-2932 Ph: (843) 972-4068 |
News Archive
Researchers have found that a rare but hard-to-treat form of breast cancer is driven by a newly discovered gene. The gene ZNF703 is the first oncogene to be discovered in five years, and it could lead to more effective treatments down the road, Cancer Research UK said.
Needle injections have been around since 1657 and remain a key delivery method for many drugs, including vaccines that have prevented countless illnesses. But for patients that require daily pricks or for people in remote locations, the syringe model has major drawbacks. An article in Chemical & Engineering News looks at potential alternatives, their successes and their roadblocks.
The vast majority of homeless adults surveyed in a national study had trouble accessing at least one type of needed health care service in the preceding year, according to a study that will appear in the July American Journal of Public Health and is now available online.
Esperance Pharmaceuticals Inc. today reported positive results from a Phase II trial of lead candidate EP-100 in ovarian cancer patients resistant to paclitaxel. EP-100 is a targeted membrane-disrupting peptide designed to seek and destroy cancer cells that overexpress luteinizing hormone-releasing hormone (LHRH) receptors on their surfaces. LHRH receptors are over-expressed in a wide range of cancers.
ISTA Pharmaceuticals, Inc. today highlighted results from the Company's REMURA (bromfenac ophthalmic solution for dry eye) Phase 2 clinical study.
› Verified 7 days ago
Sarah Parker, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 389 Johnnie Dodds Blvd, Mount Pleasant, SC 29464 Phone: 843-972-4068 | |
Taylor Marie Suydam, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1676 N Highway 17, Mount Pleasant, SC 29464 Phone: 843-884-8281 | |
Mary Catharine Knisley, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 970 Lakeview Dr, Mount Pleasant, SC 29464 Phone: 843-729-9826 | |
Cecily Victor Dipiro, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1886 Omni Blvd, Mount Pleasant, SC 29466 Phone: 843-216-6060 Fax: 843-216-6060 | |
Dr. Veronica M Owens, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 640 Long Point Rd, Mount Pleasant, SC 29464 Phone: 843-881-5644 Fax: 843-881-5685 | |
Joanna Doan Mendenhall, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1481 N Highway 17, Mount Pleasant, SC 29464 Phone: 843-881-6100 | |
Ashley Nicole Mitchell, PHARM D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1300 Long Grove Dr, Mount Pleasant, SC 29464 Phone: 843-388-8769 |